RIPK1 and myeloid sarcoma: Particularly, inhibiting RIPK1 kinase activity ameliorates microglia-mediated neuroinflammation in AD, ALS, and MS, and prevents the development of phagocytosis defective microglia, DAM, inflammatory microglia, and RRIM.